US FDA gives approval to sBLA for expanded use of Takeda’s TAKHZYRO
The US Food and Drug Administration (FDA) has given approval to Takeda’s supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to less than 12 years of age.